title: Continued use of nonsteroidal topical treatments: comment on the FDA talk paper.
authors.forename: Ronni
authors.initials: R
authors.lastname: Wolf
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Parish
authors.forename: Bat Sheva
authors.initials: BS
authors.lastname: Marcus
authors.forename: Lawrence Charles
authors.initials: LC
authors.lastname: Parish
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced*; D012871:Skin Diseases / Q000188:drug therapy; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus